CALL FOR PAPERS

CERTIFICATE

IMPACT FACTOR 2019

Subject Area

  • Life Sciences / Biology
  • Architecture / Building Management
  • Asian Studies
  • Business & Management
  • Chemistry
  • Computer Science
  • Economics & Finance
  • Engineering / Acoustics
  • Environmental Science
  • Agricultural Sciences
  • Pharmaceutical Sciences
  • General Sciences
  • Materials Science
  • Mathematics
  • Medicine
  • Nanotechnology & Nanoscience
  • Nonlinear Science
  • Chaos & Dynamical Systems
  • Physics
  • Social Sciences & Humanities

Why Us? >>

  • Open Access
  • Peer Reviewed
  • Rapid Publication
  • Life time hosting
  • Free promotion service
  • Free indexing service
  • More citations
  • Search engine friendly

Plagiarism Detection

IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.

 

 

 

 

The italian covid-19 epidemic and the global pandemic prevention and therapies

Author: 
Giulio Tarro, MD, PhD
Subject Area: 
Health Sciences
Abstract: 

The Italian management of the coronavirus epidemic by the technical scientific committee (TSC) was a failure according to an editorial in the prestigious English journal NATURE as reported in the first decade of March 2021. According to a study published in Science by the Emory University of Atlanta, the coronavirus will take on an endemic character and its lethality, i.e. mortality of the infected, will end up settling around 0.1% below seasonal flu, therefore strong social distancing. It is not the solution, the lockdown, masks, closures, hunting for the infected, blaming the people. Who gets sick must be treated, using hydroxychloroquine, azithromycin, and healing people at home. Used cortisone and heparin and avoided thrombus embolisms. People died because the correct drugs were not used. The incidence of asymptomatic positive cases in Wuhan post-lockdown was very low (0.303 / 10,000) and there was no evidence that the cases identified as positive asymptomatic were infectious. As attested by the few data made public by the pharmaceutical companies that produce them, the current vaccines do not guarantee a perennial immunity nor, even less, a “sterile immunity” to the vaccine that continues, therefore, to transmit the virus. They only promise to reduce the symptoms of the infection; symptoms that in 90-95% of the "infected" do not even manifest themselves. It would have been logical, therefore, that only the elderly were vaccinated in whom the onset of Covid represents a real danger. If seniors over 80 had been vaccinated in January as originally planned, there would have been no 500 deaths per day. Instead, a mass vaccination has been chosen which - in addition to multiplying the risks, inevitably associated with vaccines - will not guarantee even temporary herd immunity. There are currently three major genetic variants of COVID-19. these mutations typically arise when the virus is subjected to selective pressure by antibodies that limit but do not eliminate viral replication. the specific antibodies, which neutralize the virus, are still able to act on the viral "spike" protein, despite the sequence changes of the viral nucleic acid being present in the D614G variant, as in the other subsequent ones that have the purpose of allowing survival of viral particles. Protease inhibitors have been effective in the treatment of other viral pathogens such as HIV and the hepatitis C virus, both alone and in combination with other antivirals. Currently commercialized therapies that target viral proteases are generally not associated with toxicity and as such, this class of molecules can potentially provide well-tolerated treatments against COVID-19.

PDF file: 

IJMCE RECOMMENDATION

ONLINE PAYPAL PAYMENT

CURRENT ISSUE

NEWS

CHIEF EDITOR
Rosane Cavalcante Fragoso, Brasil
ASSOCIATE CHIEF EDITOR

   

Jean-Marc SABATIER
Chief Scientific Officer and Head of a Research Group
France

Advantages of IJCR

  • Rapid Publishing
  • Professional publishing practices
  • Indexing in leading database
  • High level of citation
  • High Qualitiy reader base
  • High level author suport

EDITORIAL BOARD

Luai Farhan Zghair
Iraq
Hasan Ali Abed Al-Zu’bi
Jordanian
Fredrick OJIJA
Tanzanian
Firuza M. Tursunkhodjaeva
Uzbekistan
Faraz Ahmed Farooqi
Saudi Arabia
Eric Randy Reyes Politud
Philippines
Elsadig Gasoom FadelAlla Elbashir
Sudan
Eapen, Asha Sarah
United State
Dr.Arun Kumar A
India
Dr. Zafar Iqbal
Pakistan
Dr. SHAHERA S.PATEL
India
Dr. Ruchika Khanna
India
Dr. Recep TAS
Turkey
Dr. Rasha Ali Eldeeb
Egypt
Dr. Pralhad Kanhaiyalal Rahangdale
India
DR. PATRICK D. CERNA
Philippines
Dr. Nicolas Padilla- Raygoza
Mexico
Dr. Mustafa Y. G. Younis
Libiya
Dr. Muhammad shoaib Ahmedani
Saudi Arabia
DR. MUHAMMAD ISMAIL MOHMAND
United State
DR. MAHESH SHIVAJI CHAVAN
India
DR. M. ARUNA
India
Dr. Lim Gee Nee
Malaysia
Dr. Jatinder Pal Singh Chawla
India
DR. IRAM BOKHARI
Pakistan
Dr. FARHAT NAZ RAHMAN
Pakistan
Dr. Devendra kumar Gupta
India
Dr. ASHWANI KUMAR DUBEY
India
Dr. Ali Seidi
Iran
Dr. Achmad Choerudin
Indonesia
Dr Ashok Kumar Verma
India
Thi Mong Diep NGUYEN
France
Dr. Muhammad Akram
Pakistan
Dr. Imran Azad
Oman
Dr. Meenakshi Malik
India
Aseel Hadi Hamzah
Iraq
Anam Bhatti
Malaysia
Md. Amir Hossain
Bangladesh
Ahmet İPEKÇİ
Turkey
Mirzadi Gohari
Iran